Search

Your search keyword '"JELAKOVIĆ, BOJAN"' showing total 823 results

Search Constraints

Start Over You searched for: Author "JELAKOVIĆ, BOJAN" Remove constraint Author: "JELAKOVIĆ, BOJAN"
823 results on '"JELAKOVIĆ, BOJAN"'

Search Results

107. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

108. Repositioning of the global epicentre of non- optimal cholesterol

109. RETROPERITONEALNA FIBROZA: RIJEDAK OBLIK PARANEOPLASTIČNOG SINDROMA U SKLOPU KARCINOMA PLUĆA

110. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: Consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient

111. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.

112. UDIO BOLESNIKA NA LISTI ČEKANJA ZA TRANSPLANTACIJU BUBREGA I PRIDRUŽENE BOLESTI – IMA LI MJESTA ZA POBOLJŠANJE?

113. Epidemiology of Hypertension and salt intake in Croatia (EH-UH2)

114. The Position of the Croatian Society of Hypertension on the Observed Increase in Risk of Non-melanoma Skin Cancer Associated with Hydrochlorothiazide Treatment

115. INTER-ARM BLOOD PRESSURE DIFFERENCE AND MORTALITY – EPIDEMIOLOGY OF HYPERTENSION IN CROATIA (EHUH STUDY)

116. OBESITY AND MORTALITY - RESULTS FROM THE EPIDEMIOLOGY OF HYPERTENSION IN CROATIA (EHUH STUDY) - MORTALITY DATA AFTER 17 YEARS OF FOLLOW- UP

117. Rising rural body-mass index is the main driver of the global obesity epidemic in adults

118. Praktične smjernice za dijagnostiku i liječenje arterijske hipertenzije u djece i adolescenata

119. EPIDEMIOLOGY OF HYPERTENSION IN CROATIA (EHUH STUDY)- MORTALITY DATA AFTER 17 YEARS OF FOLLOW-UP

120. Risk assessment for cancer development associated with the use of antihypertensives

124. Hypoproteinemia as a prognostic risk factor for arteriovenous fistula failure

125. Debljina i hipertenzija

126. Citrinin in endemic nephropathy

127. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants

128. Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It?

129. Fibromuskularna displazija

130. Epidemiologija arterijske hipertenzije i unos kuhinjske soli u Hrvatskoj (EH-UH 2)

132. Treatment of Hypertension Induced Albuminuria

133. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol

137. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: A randomised controlled trial protocol

138. Utjecaj urične kiseline na arterijski tlak i vaskularnu funkciju kod mladih odraslih muškaraca rođenih nakon intrauterinog zastoja u rastu

139. PREHYPERTENSION AND SINGLE NUCLEOTIDE POLYMORPHISM RS13333226 OF THE UROMODULIN (UMOD) GENE

140. Endemska nefropatija – primjer kasnijeg vaskularnog starenja

141. BOLESNIK S HEPATITISOM C I MEMBRANSKOM NEFROPATIJOM

142. Hrvatska aplikacija za poboljšanje kontrole arterijske hipertenzije

143. Continuous Veno-Venous Hemofiltration Improves Survival of Patients With Congestive Heart Failure and Cardiorenal Syndrome Compared to Slow Continuous Ultrafiltration

144. BIOPSIJA BUBREGA POD KONTROLOM MSCT-A – METODA IZBORA U KOMPLICIRANIM SLUČAJEVIMA

147. Uromodulin – Moguća uloga u aterosklerozi?

148. Praktične smjernice za postavljanje dijagnoze arterijske hipertenzije Hrvatskog društva za arterijsku hipertenziju Hrvatskoga liječničkog zbora i Radne skupine za arterijsku hipertenziju Hrvatskoga kardiološkog društva

149. UČINKOVITOST MIKOFENOLAT-MOFETILA U REZISTENTNIM PRIMARNIM GLOMERULARNIM BOLESTIMA

150. Aristolactam-DNA adducts anre a biomarket of environmental exposure to aristolochic acid out of established endemice nephropathy rural villages

Catalog

Books, media, physical & digital resources